Business Wire

Notice of Multi-Color First Quarter 2026 Financial Results Conference Call

4.6.2026 05:56:00 CEST | Business Wire | Press Release

Share

Multi-Color Corporation (“MCC”) First Quarter 2026 Financial Results Conference Call covering MCC’s performance for the quarter ending March 31, 2026.

When:
Monday, June 8th at 10:00 A.M. EDT

Leaders:
Hassan Rmaile, President & CEO and Kathleen Phelps, CFO

Access:
Existing and prospective investors can gain access to the investor data site (“Data Site”) by following the instructions section 2 below. If you previously had access to the investor data site then no action is needed as your access remains in place. Please submit access requests to the email address listed below in section 2 by 5pm ET Friday, June 5th. The live link to the first quarter 2026 financial results call will be posted to the investor data site.

Investor Data Site Access Instructions:

1. Data site access

Common Unit, Preferred Unit and Warrant holders of Labels Buyer, LLC (“Company”), holders of notes issued by Multi-Color Corporation and MCC Manufacturing, Inc. (collectively, the “Issuers”) and prospective investors (“Investors”), securities analysts (to the extent providing analysis of an investment in the Company’s and the Issuers’ securities, as well certain market making institutions, can access the Company’s investor data site (the “Data Site”).

2. Request Data Site access

If you need access to the Data Site please complete the attached access request document on our website and submit to investor.relations@mcclabel.com

The document can be accessed here.

  • Data Site access may only be granted to:
  1. each unitholder of the Company that is not a “Competitor” (as defined below) and who is a party to the Company’s Third Amended and Restated Limited Liability Company Agreement, dated as of May 11, 2026 (as the same may be amended or restated from time to time (the “Agreement”) and acknowledges and agrees to its confidentiality obligations in respect of information available on the Data Site;

  2. each warrantholder of the Company that is not a Competitor and acknowledges and agrees to its confidentiality obligations in respect of information available on the Data Site;

  3. to any bona fide prospective investor of units and/or warrants of the Company that is not a Competitor, who requests access to the Data Site and certifies that it is a “qualified institutional buyer” within the meaning of Rule 144A of the Securities Act or non-U.S. persons (as defined in Regulation S under the Securities Act) and agrees (x) to its confidentiality obligations in respect of information available on the Data Site, and (y) to deliver an executed joinder to the Agreement (a “Joinder”) to the Company in connection with any acquisition of units of the Company;

  4. each holder of notes issued by the Issuers;

  5. to any prospective investors in the notes issued by the Issuers that is not a Competitor who requests access to the Data Site and certifies that it is a “qualified institutional buyer” within the meaning of Rule 144A of the Securities Act; or

  6. to securities analysts (to the extent providing research and analysis of investment in the units of the Company or the notes issued by the Issuers) and select market-making financial institutions.

    “Competitor” means a company (i) whose primary business is in the same or a similar line of business as the Company or its subsidiaries or (ii) who is otherwise competitive with the Company or its subsidiaries in any non-de minimis respect, and for this purpose, “Competitor” shall include an affiliate of any Person described in clause (i) or (ii) above; provided that, an asset manager or investment firm that, as part of their investment portfolios, controls or manages entities that compete with the Company and its subsidiaries, shall not be deemed to be a “Competitor” so long as such asset managers or investment firms maintain and enforce effective information barriers that prevent the flow of confidential information regarding the Company and its subsidiaries to any portfolio company controlled by such asset manager or investment firm.

Investors that became unitholders of the Company as of the effective date of the Joint Prepackaged Plan of Reorganization of Multi-Color Corporation Inc. and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code (the “Plan”) (i.e., May 11, 2026) (such unitholders, the “Original Holders”) were deemed, pursuant to the Plan, to have executed the Agreement without the need to deliver signature pages or joinders thereto.

If you are an existing unitholder of the Company and you were not an Original Holder and you have not yet submitted a Joinder, please access the Data Site referenced above to view the Joinder, which should be executed and emailed with such information as the Company may reasonably request, to: legal@mcclabel.com.

___________________________________________________________________________

Multi-Color Corporation does not make its financial information available to the public. Access to the call is restricted to holders of the securities issued by Labels Buyer, LLC and its subsidiaries, qualified prospective investors in such securities, and certain securities analysts and market makers who have registered for access to the secured data site.

A recording of the call will be available soon on Multi-Color’s Investor secured data site.

About Multi-Color Corporation

Multi-Color Corporation (MCC), established in 1916, is the global leader in prime label solutions, with approximately $3 billion in annual revenue supporting a number of the world’s most prominent brands across end-categories including food and beverages, home and personal care, wine and spirits, and other specialties. Based in Atlanta, MCC serves national and international brand owners across its global footprint with a comprehensive range of the latest label technologies in pressure sensitive, cut and stack, roll-fed, in-mold, shrink sleeve and heat transfer applications. MCC employs approximately 12,275 associates across more than 90 plants in over 25 countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260603368352/en/

Contacts

James Waters
james.waters@mcclabel.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye